1. Generics Bulletin
  2. >>Business
  3. >>Deals

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

New Jersey-Based Slayback Founded A Decade Ago; Received KKR, Everstone Investments

 
• By Dean Rudge

In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

Mergers & Acquisitions - Image
• Source: Shutterstock

Azurity Pharmaceuticals, a Massachusetts-based firm focused on the 505(b)(2) hybrid new drug application pathway, says it looks forward to bringing its commercial expertise to Slayback Pharma’s pipeline after acquiring the New Jersey-based 505(b)(2) and complex generics firm for an undisclosed fee.

Announcing its completion of a deal for Slayback from existing investors including KKR and Everstone Capital, Azurity said the acquisition “brings together companies with complementary strengths, enhancing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business